text: The mainstay of management of VWD is<unk><unk> .<unk><unk>  of<unk><unk> 's<unk>  ( vWD) involves normalizing the<unk><unk>  factor and factor VIII levels. Endogenous factor levels can be increased by the use of desmopressin or by infusing exogenous coagulation factors example high-purity or low-purity<unk><unk>  factor concentrate.<unk><unk>  depends on the type of<unk><unk> 's<unk> . Desmopressin is used for type 1 and 2<unk><unk> 's<unk> .<unk><unk>  factor-factor VIII or<unk><unk>  factor concentrate is used in some of type 2<unk><unk> 's<unk>  and all of type 3<unk><unk> 's<unk> . Alternate  or additional<unk>  involves the use of tranexamic acid or aminocaproic acid.
option_0: Von Willebrand disease medical therapy
option_1: Antithrombin III deficiency medical therapy
option_2: Glanzmann's thrombasthenia medical therapy
option_3: Antiphospholipid syndrome medical therapy
option_4: Disseminated intravascular coagulation medical therapy
option_5: Essential thrombocytosis medical therapy
option_6: Thrombophilia medical therapy
option_7: Heparin-induced thrombocytopenia medical therapy